LAVAMED
ActiveSummary
LAVAMED has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €158,761 and a net result of €95,896. Equity is growing by about 45% per year across the filed financial years. Its solvency ranks better than 24% of 20,612 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
31-08
NBB filing
Annual accounts filed
financial year 2025 · micro format · 31 days late
2025
31-12
Financial
Back to profitnet €95,896
Net result €95,896 after one loss-making year.
31-12
Financial
Equity above €150,000equity €158,761 ▲153%
Equity rises from €62,865 to €158,761.
28-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 28 days late
2024
31-12
Financial
Weakest financial yearnet -€20,861
Net result drops to -€20,861, the lowest in the series; recovery starts the following year.
31-12
Financial
Liquidity more than doubledcurrent ratio 1.27
Current ratio from 0.54 to 1.27.
18-10
NBB filing
Annual accounts filed
financial year 2023 · micro format · 79 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.